Drug Type Small molecule drug |
Synonyms Beraprost Sodium, Esuberaprost, Esuberaprost potassium + [8] |
Target |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (17 Jan 1994), |
Regulation- |
Molecular FormulaC24H30NaO5 |
InChIKeyLJCCZMFYFWMMDN-ZTWNIFTGSA-N |
CAS Registry152695-53-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10703 | - | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 30 Sep 1999 | |
Peripheral Vascular Diseases | JP | 10 Sep 1996 | |
Peripheral Vascular Diseases | JP | 10 Sep 1996 | |
Occlusion of artery | KR | 17 Jan 1994 | |
Pulmonary Arterial Hypertension | KR | 17 Jan 1994 | |
Ulcer | KR | 17 Jan 1994 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Arteriosclerosis | Phase 2 | JP | 03 Dec 2003 | |
Diabetic Neuropathies | Phase 2 | JP | 30 May 2001 | |
Neoplasms | Phase 1 | US | 09 Dec 2002 |
Phase 3 | 112 | (Esuberaprost) | btjhorkgom(zxliubhzxb) = eipbfndipa vrphvagais (xzljcwtjqf, cqsgbgjfhk - rtqqdlburm) View more | - | 07 Sep 2020 | ||
Placebo+Esuberaprost (Placebo/Esuberaprost) | btjhorkgom(zxliubhzxb) = dpftrpxacb vrphvagais (xzljcwtjqf, futgexbqap - scqczdlbav) View more | ||||||
Phase 3 | - | mhycwzwbve(gkwbiiaaey) = not meet xztvfdyrbb (pqpcryguhp ) | Negative | 08 Apr 2019 |